Seres Therapeutics vs Ovid Therapeutics
Ovid Therapeutics is the larger business, with $7.3m of revenue in fiscal 2025 against $789,000 for Seres Therapeutics (9.2 times as much). Seres Therapeutics kept more of each dollar of sales as profit: a net margin of 721.9% against -240.1%.
| Latest fiscal year | Seres TherapeuticsMCRB, 2025 | Ovid TherapeuticsOVID, 2025 |
|---|---|---|
| Revenue | $789,000 | $7.3m |
| Revenue growth | — | 1181.3% |
| Net income | $5.7m | −$17.4m |
| Operating margin | — | -585.2% |
| Net margin | 721.9% | -240.1% |
| Return on equity | 19.6% | -17.5% |
| Free cash flow | $865,000 | −$38.3m |
| Cash | $45.8m | $13.2m |
| Total debt | $0 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 66 | 23 |
| Market value | $18.9m | $446m |
| Price vs our value range | Below our value range | — |
| Moat score | 10 (Weak) | 10 (Weak) |
| Insider trades, 12 months | 0 buys, 16 sales | 0 buys, 2 sales |